Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women
Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Humans
Exciting advances have led to the concept that hormones can modulate appetite and food intake. Oxytocin is a peptide hormone that is released in regions throughout the brain, including areas involved in food motivation. Animal studies suggest that oxytocin may reduce food intake. The effects of oxytocin administration on eating behavior in humans, which could have important implications in eating-related disorders ranging from obesity to anorexia nervosa, have not been investigated. This double-blind placebo-controlled cross-over study of single-dose oxytocin administration investigates whether:
- Caloric intake will decrease following administration of oxytocin versus placebo
- Appetite will decrease following administration of oxytocin versus placebo
- Resting energy expenditure will increase following administration of oxytocin versus placebo
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-45 years old
- BMI 18.5-24.9, 25-40
- Regular breakfast eater (at least 4 times per week)
- Stable weight within the past three months
Exclusion Criteria:
- Psychiatric disease
- Use of psychotropic medications
- History of eating disorder
- History of excessive exercise within the last three months
- History of diabetes mellitus
- Active substance abuse
- Hematocrit below normal range
- Gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection)
- History of cardiovascular disease (such as hypertrophic cardiomyopathy, valvular heart disease, coronary heart disease, or coronary artery spasms)
- Untreated thyroid disease
- Tobacco use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Oxytocin
Intranasal oxytocin
|
Intranasal oxytocin 24 IU single-dose administration
Other Names:
|
|
Placebo Comparator: Placebo
Intranasal placebo
|
Intranasal Placebo single-dose administration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Caloric intake
Time Frame: +60 minutes after drug/placebo
|
+60 minutes after drug/placebo
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Appetite
Time Frame: +55 (fasting) and +90 minutes (post-prandial) after drug/placebo
|
Assessed using a Visual Analogue Scale
|
+55 (fasting) and +90 minutes (post-prandial) after drug/placebo
|
|
Resting energy expenditure
Time Frame: +30 minutes after drug/placebo
|
Assessed using metabolic cart
|
+30 minutes after drug/placebo
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elizabeth A Lawson, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MGH1004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.